Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies

被引:42
作者
Kawauchi, Kiyotaka [1 ]
Ogasawara, Toshie [1 ]
Yasuyama, Masako [1 ]
Otsuka, Kuniaki [1 ]
Yamada, Osamu [2 ]
机构
[1] Tokyo Womens Med Univ, Med Ctr E, Dept Med, Tokyo, Japan
[2] Tokyo Womens Med Univ, Med Res Inst, Tokyo, Japan
关键词
PI3K; Akt; mTOR; hematologic malignancies; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; CELL-CYCLE ARREST; ENDOTHELIAL GROWTH-FACTOR; MTOR INHIBITOR CCI-779; PROTEIN-KINASE-B; CONSTITUTIVE ACTIVATION; PHOSPHATIDYLINOSITOL; 3-KINASE; BCR-ABL;
D O I
10.2174/187152009789377772
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphatidylinositol 3-kinase (PI3K), a heterodimeric lipid kinase, is a key enzyme in signal transduction from various stimuli to downstream pathways that elicit diverse responses involving growth, proliferation, survival, differentiation, and metabolism in many cellular systems. Activated PI3K generates phosphatidylinositol-3,4,5-triphosphate, which recruits phosphatidylinositol-dependent kinase 1 (PDK1) and Akt serine/threonine kinase at the plasma membrane, resulting in activation of Akt. In turn, Akt activates multiple downstream targets, most notably the mTOR pathway. There is abundant evidence implicating the PI3K/Akt/mTOR pathway in the development and progression of a variety of tumors including hematologic neoplasms. Therefore, this pathway is considered a critical target for cancer therapy. We review the regulatory mechanisms of the PI3K/Akt/mTOR signaling pathway and the role of this pathway in oncogenesis of hematological malignancies.
引用
收藏
页码:1024 / 1038
页数:15
相关论文
共 175 条
[1]   Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders [J].
Aggerholm, A ;
Gronbæk, K ;
Guldberg, P ;
Hokland, P .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2000, 65 (02) :109-113
[2]  
Akiyama M, 2002, CANCER RES, V62, P3876
[3]   HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation [J].
Akl, H. ;
Badran, B. M. ;
Zein, N. E. ;
Bex, F. ;
Sotiriou, C. ;
Willard-Gallo, K. E. ;
Burny, A. ;
Martiat, P. .
LEUKEMIA, 2007, 21 (04) :788-796
[4]   The survival kinases Akt and Pim as potential pharmacological targets [J].
Amaravadi, R ;
Thompson, CB .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2618-2624
[5]   Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway [J].
Bai, RY ;
Tao, OY ;
Miething, C ;
Morris, SW ;
Peschel, C ;
Duyster, J .
BLOOD, 2000, 96 (13) :4319-4327
[6]  
BELLACOSA A, 1993, ONCOGENE, V8, P745
[7]  
Bellamy WT, 1999, CANCER RES, V59, P728
[8]   Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells [J].
Bellon, Marcia ;
Nicot, Christophe .
BLOOD, 2008, 112 (07) :2946-2955
[9]   Survival of leukemic B cells promoted by engagement of the antigen receptor [J].
Bernal, A ;
Pastore, RD ;
Asgary, Z ;
Keller, SA ;
Cesarman, E ;
Liou, HC ;
Schattner, EJ .
BLOOD, 2001, 98 (10) :3050-3057
[10]   The two TORCs and Akt [J].
Bhaskar, Prashanth T. ;
Hay, Nissim .
DEVELOPMENTAL CELL, 2007, 12 (04) :487-502